Patents by Inventor MILAD BITAR

MILAD BITAR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8735443
    Abstract: The method of treating diabetes-related vascular complications includes the treatment of diabetic patients with ?-lipoic acid (LA) in order to mitigate the negative impact of diabetes-related vascular dysfunctions upon vascular homeostasis. The treatment method includes the step of administering to the patient an initial dosage of ?-lipoic acid believed to be therapeutically effective. The patient's response is then monitored by measuring ?-lipoic acid-responsive biomarkers and by performing assays from blood and tissue taken from the patient.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: May 27, 2014
    Assignee: Kuwait University
    Inventors: Fahd Al-Mulla, Milad Bitar
  • Patent number: 8637461
    Abstract: The method of diagnosing and treating oxidative stress-impaired wound healing allows a practitioner to identify a subject at risk of having impaired wound healing by identifying the sensitivity of that patient to IGF-1. A finding of IGF-1 resistance, either systemically or at the site of an already existing wound, indicates an increased likelihood that the wound will have difficulty healing. In addition, identifying IGF-1 resistance by this method indicates that treatment of a wound with a combination of an antioxidant, IGF-1 and IGFBP-1 will provide optimal healing.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: January 28, 2014
    Assignee: Kuwait University
    Inventors: Fahd Al-Mulla, Milad Bitar
  • Publication number: 20130171273
    Abstract: The method of treating impaired wound healing in diabetics comprises the step of administering an effective amount of a glycogen synthase kinase 3-? (GSK-3?) inhibitor to a diabetic patient in need thereof to activate the NF-E2-related factor 2 (Nrf2) and genes downstream of Nrf2 that normally regulate the expression and coordination of antioxidant responses during wound healing, but are suppressed in the diabetic patient undergoing the oxidative stress that can occur during wound healing. The GSK-3? inhibitor may be lithium or a pharmaceutically acceptable salt thereof, or TDZD-8 (4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione). The method may further comprise the step of testing the diabetic patient for the presence of oxidative stress and decreased Nrf2, which enables the early or prophylactic treatment of the patient with a GSK-3? inhibitor when the patient first presents with a wound, rather than waiting for other symptoms of impaired wound healing to occur.
    Type: Application
    Filed: December 28, 2011
    Publication date: July 4, 2013
    Applicant: KUWAIT UNIVERSITY
    Inventors: FAHD AL-MULLA, MILAD BITAR
  • Publication number: 20130172253
    Abstract: The method of diagnosing and treating oxidative stress-impaired wound healing allows a practitioner to identify a subject at risk of having impaired wound healing by identifying the sensitivity of that patient to IGF-1. A finding of IGF-1 resistance, either systemically or at the site of an already existing wound, indicates an increased likelihood that the wound will have difficulty healing. In addition, identifying IGF-1 resistance by this method indicates that treatment of a wound with a combination of an antioxidant, IGF-1 and IGFBP-1 will provide optimal healing.
    Type: Application
    Filed: December 28, 2011
    Publication date: July 4, 2013
    Applicant: KUWAIT UNIVERSITY
    Inventors: FAHD AL-MULLA, MILAD BITAR
  • Publication number: 20120052051
    Abstract: The method of treating diabetes-related vascular complications includes the treatment of diabetic patients with ?-lipoic acid (LA) in order to mitigate the negative impact of diabetes-related vascular dysfunctions upon vascular homeostasis. The treatment method includes the step of administering to the patient an initial dosage of ?-lipoic acid believed to be therapeutically effective. The patient's response is then monitored by measuring ?-lipoic acid-responsive biomarkers and by performing assays from blood and tissue taken from the patient.
    Type: Application
    Filed: August 15, 2011
    Publication date: March 1, 2012
    Applicant: KUWAIT UNIVERSITY
    Inventors: FAHD AL-MULLA, MILAD BITAR